Kiyoshi Mizuguchi

No ORCID on file · 5 papers in corpus
lab-animal 2012
Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E₂ production in human endometriotic stromal cells in spheroid culture
Fertility and sterility ·doi:10.1016/j.fertnstert.2011.11.005

OBJECTIVE: To determine the effect of dienogest (DNG) on the expression of aromatase and cyclooxygenase-2 (COX-2) and the production of prostaglandin E(2) (PGE(2)) in human endometriotic stromal cells (ESCs). DESIGN: Experimental study in …

lab-animal 2010
Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system
Steroids ·doi:10.1016/j.steroids.2010.08.010

Prostaglandin E(2) (PGE(2)) is a major mediator in the pathophysiology, and pathogenesis of gynecological diseases associated with abnormal endometrial disease with proliferation and inflammation, such as endometriosis. In this study, we in…

lab-animal 2009
Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression
Molecular human reproduction ·doi:10.1093/molehr/gap042

Dienogest is a specific progesterone receptor agonist with potent oral endometrial activity and is used in the treatment of endometriosis. In this study, we examined the direct effects of dienogest on the proliferation of human endometrial …

review 2009
[Pharmacological and clinical profile of dienogest (DINAGEST Tab. 1 mg)]
Nihon yakurigaku zasshi. Folia pharmacologica Japonica ·doi:10.1254/fpj.133.32
lab-animal 2007
Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile
Steroids ·doi:10.1016/j.steroids.2007.10.003

Dienogest was introduced as an oral progestin. Yet its strong oral potency on endometrial activity is not clearly explained. To circumvent this situation, steroid hormone receptor profiling using transactivation assay and endometrial activi…